Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Wilson

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Frontiers in Reproductive Health|October 28, 2022
"<i>They Just Tell Me to Abstain:"</i> Variable Access to and Uptake of Sexual and Reproductive Health Services Among Adolescents Living With HIV in KenyaSarah Lawrence, Hellen Moraa, Kate Wilson, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
BMJ Open|January 18, 2024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trialsZoe McQuilten, Stephane Heritier, Lucy Fox, et al.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
Genome Medicine|April 13, 2021
Functional interpretation of ATAD3A variants in neuro-mitochondrial phenotypesZheng Yie Yap, Yo Han Park, Saskia B Wortmann, et al.
BMC Cancer|August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
BMJ Open|February 3, 2025
Pathway Of Low Anterior Resection syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancerJulie Croft, Emily Farrow, Alexandra Harriet Coxon-Meggy, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Frontiers in Reproductive Health|October 28, 2022
"<i>They Just Tell Me to Abstain:"</i> Variable Access to and Uptake of Sexual and Reproductive Health Services Among Adolescents Living With HIV in KenyaSarah Lawrence, Hellen Moraa, Kate Wilson, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
BMJ Open|January 18, 2024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trialsZoe McQuilten, Stephane Heritier, Lucy Fox, et al.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
Genome Medicine|April 13, 2021
Functional interpretation of ATAD3A variants in neuro-mitochondrial phenotypesZheng Yie Yap, Yo Han Park, Saskia B Wortmann, et al.
BMC Cancer|August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
BMJ Open|February 3, 2025
Pathway Of Low Anterior Resection syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancerJulie Croft, Emily Farrow, Alexandra Harriet Coxon-Meggy, et al.
Pageof 10